{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:37:10Z","timestamp":1793673430211,"version":"4.5.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-026-01689-5","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:03:34Z","timestamp":1781168614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Skeletal-muscle-targeted non-viral delivery of full-length DMD mRNA for Duchenne muscular dystrophy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1919-0614","authenticated-orcid":false,"given":"Yu","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhao","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Huntoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6564-501X","authenticated-orcid":false,"given":"Liqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-4365","authenticated-orcid":false,"given":"Yifan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-8895","authenticated-orcid":false,"given":"Shiyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5163-3924","authenticated-orcid":false,"given":"Seong Dong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreanne Poppy","family":"Estania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Joo","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-0654","authenticated-orcid":false,"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8343-4748","authenticated-orcid":false,"given":"Annette","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7604-3441","authenticated-orcid":false,"given":"Jared L.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Tzu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-4240","authenticated-orcid":false,"given":"Adam J.","family":"Grippin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6350-4455","authenticated-orcid":false,"given":"Zhaogang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3589-0280","authenticated-orcid":false,"given":"Ly James","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Bahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-633X","authenticated-orcid":false,"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-4014","authenticated-orcid":false,"given":"Feng","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-8355","authenticated-orcid":false,"given":"Betty Y. S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9169-1481","authenticated-orcid":false,"given":"Andrew S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"1689_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman, E. P., Brown, R. H. Jr & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919\u2013928 (1987).","journal-title":"Cell"},{"key":"1689_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Primers. 7, 13 (2021).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"1689_CR3","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart, I. E. C. & Aartsma-Rus, A. Therapeutic developments for Duchenne muscular dystrophy. Nat. Rev. Neurol. 15, 373\u2013386 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"1689_CR4","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ncb1596","volume":"9","author":"H Valadi","year":"2007","unstructured":"Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654\u2013659 (2007).","journal-title":"Nat. Cell Biol."},{"key":"1689_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257\u2013271 (2016).","journal-title":"Ann. Neurol."},{"key":"1689_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza, V. et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum. Gene Ther. 18, 798\u2013810 (2007).","journal-title":"Hum. Gene Ther."},{"key":"1689_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nrg1180","volume":"4","author":"JC Van Deutekom","year":"2003","unstructured":"Van Deutekom, J. C. & van Ommen, G. J. Advances in Duchenne muscular dystrophy gene therapy. Nat. Rev. Genet. 4, 774\u2013783 (2003).","journal-title":"Nat. Rev. Genet."},{"key":"1689_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen, C. L. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395\u2013402 (2015).","journal-title":"Hum. Mutat."},{"key":"1689_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais, L. et al. Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1\/2 trial. Nucleic Acid Ther. 32, 29\u201339 (2022).","journal-title":"Nucleic Acid Ther."},{"key":"1689_CR10","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens, P. R. et al. Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 77, 982\u2013991 (2020).","journal-title":"JAMA Neurol."},{"key":"1689_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner, K. R. et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 64, 285\u2013292 (2021).","journal-title":"Muscle Nerve"},{"key":"1689_CR12","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90, e2146\u2013e2154 (2018).","journal-title":"Neurology"},{"key":"1689_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JND-200548","volume":"8","author":"JR Mendell","year":"2021","unstructured":"Mendell, J. R. et al. Comparison of long-term ambulatory function in patients with Duchenne muscular dystrophy treated with eteplirsen and matched natural history controls. J. Neuromuscul. Dis. 8, 469\u2013479 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"1689_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald, C. M. et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J. Neuromuscul. Dis. 8, 989\u20131001 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"1689_CR15","first-page":"835","volume":"45","author":"JT Den Dunnen","year":"1989","unstructured":"Den Dunnen, J. T. et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am. J. Hum. Genet. 45, 835\u2013847 (1989).","journal-title":"Am. J. Hum. Genet."},{"key":"1689_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/0888-7543(92)90437-W","volume":"12","author":"AJ Coffey","year":"1992","unstructured":"Coffey, A. J. et al. Construction of a 2.6-Mb contig in yeast artificial chromosomes spanning the human dystrophin gene using an STS-based approach. Genomics 12, 474\u2013484 (1992).","journal-title":"Genomics"},{"key":"1689_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0888-7543(92)90436-V","volume":"12","author":"AP Monaco","year":"1992","unstructured":"Monaco, A. P., Walker, A. P., Millwood, I., Larin, Z. & Lehrach, H. A yeast artificial chromosome contig containing the complete Duchenne muscular dystrophy gene. Genomics 12, 465\u2013473 (1992).","journal-title":"Genomics"},{"key":"1689_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","volume":"53","author":"M Koenig","year":"1988","unstructured":"Koenig, M., Monaco, A. P. & Kunkel, L. M. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219\u2013228 (1988).","journal-title":"Cell"},{"key":"1689_CR19","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan, D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337\u20132356 (2018).","journal-title":"Mol. Ther."},{"key":"1689_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ymthe.2019.01.019","volume":"27","author":"KE Davies","year":"2019","unstructured":"Davies, K. E. & Guiraud, S. Micro-dystrophin genes bring hope of an effective therapy for Duchenne muscular dystrophy. Mol. Ther. 27, 486\u2013488 (2019).","journal-title":"Mol. Ther."},{"key":"1689_CR21","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths. Nat. Biotechnol. 38, 910 (2020).","DOI":"10.1038\/s41587-020-0642-9"},{"key":"1689_CR22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati, T. et al. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 21, 814\u2013829 (2022).","journal-title":"Lancet Neurol."},{"key":"1689_CR23","unstructured":"The Pfizer DMD Gene Therapy Team. DMD Study 1001 update: letter to the community. Pfizer https:\/\/www.parentprojectmd.org\/wp-content\/uploads\/2021\/12\/DMD-Study-1001-Update_Letter-to-the-Community.pdf (2021)."},{"key":"1689_CR24","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","volume":"389","author":"A Lek","year":"2023","unstructured":"Lek, A. et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 389, 1203\u20131210 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1689_CR25","unstructured":"Belluscio, B. et al. Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1B study. MDA https:\/\/www.mdaconference.org\/abstract-library\/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study\/ (2020)."},{"key":"1689_CR26","unstructured":"Wexler, M. Phase 3 trial of Pfizer\u2019s gene therapy expected to open in US in June. Muscular Dystrophy News Today https:\/\/musculardystrophynews.com\/news\/phase-3-trial-of-pfizers-gene-therapy-expected-to-open-in-us-in-june\/ (2022)."},{"key":"1689_CR27","unstructured":"Masson, G. Update: young boy\u2019s fatal cardiac arrest prompts dosing pause in Pfizer\u2019s phase 3 gene therapy trial. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/pfizer-reports-death-young-boy-dmd-who-participated-gene-therapy-trial (2024)."},{"key":"1689_CR28","unstructured":"Mason, G. Update: Pfizer\u2019s phase 3 gene therapy trial fails to improve function for boys with Duchenne muscular dystrophy. Fierce Biotech https:\/\/www.fiercebiotech.com\/biotech\/pfizers-phase-3-gene-therapy-trial-fails-improve-function-boys-duchenne-muscular-dystrophy (2024)."},{"key":"1689_CR29","doi-asserted-by":"publisher","first-page":"20507","DOI":"10.1021\/jacs.2c09484","volume":"144","author":"Z Yuan","year":"2022","unstructured":"Yuan, Z. et al. Mitigating the immunogenicity of AAV-mediated gene therapy with an immunosuppressive phosphoserine-containing zwitterionic peptide. J. Am. Chem. Soc. 144, 20507\u201320513 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1689_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/hum.2018.144","volume":"29","author":"H Khabou","year":"2018","unstructured":"Khabou, H., Cordeau, C., Pacot, L., Fisson, S. & Dalkara, D. Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity. Hum. Gene Ther. 29, 1235\u20131241 (2018).","journal-title":"Hum. Gene Ther."},{"key":"1689_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"1689_CR32","doi-asserted-by":"publisher","first-page":"eabd0321","DOI":"10.1126\/sciadv.abd0321","volume":"7","author":"PO Ilyinskii","year":"2021","unstructured":"Ilyinskii, P. O. et al. Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles. Sci. Adv. 7, eabd0321 (2021).","journal-title":"Sci. Adv."},{"key":"1689_CR33","unstructured":"[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients. Roche https:\/\/www.roche.com\/investors\/updates\/inv-update-2025-06-15 (2025)."},{"key":"1689_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Karik\u00f3, K. & T\u00fcreci, \u00d6. mRNA-based therapeutics\u2014developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1689_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1689_CR36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1096\/fba.2021-00045","volume":"3","author":"S Busatto","year":"2021","unstructured":"Busatto, S., Morad, G., Guo, P. & Moses, M. A. The role of extracellular vesicles in the physiological and pathological regulation of the blood\u2013brain barrier. FASEB Bioadv. 3, 665\u2013675 (2021).","journal-title":"FASEB Bioadv."},{"key":"1689_CR37","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","volume":"16","author":"IK Herrmann","year":"2021","unstructured":"Herrmann, I. K., Wood, M. J. A. & Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 16, 748\u2013759 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"1689_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-022-00410-w","volume":"21","author":"L Cheng","year":"2022","unstructured":"Cheng, L. & Hill, A. F. Therapeutically harnessing extracellular vesicles. Nat. Rev. Drug Discov. 21, 379\u2013399 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1689_CR39","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.accounts.9b00109","volume":"52","author":"OG De Jong","year":"2019","unstructured":"De Jong, O. G. et al. Drug delivery with extracellular vesicles: from imagination to innovation. Acc. Chem. Res. 52, 1761\u20131770 (2019).","journal-title":"Acc. Chem. Res."},{"key":"1689_CR40","doi-asserted-by":"publisher","first-page":"9155","DOI":"10.1073\/pnas.1605146113","volume":"113","author":"E Nolte-\u2018t Hoen","year":"2016","unstructured":"Nolte-\u2018t Hoen, E., Cremer, T., Gallo, R. C. & Margolis, L. B. Extracellular vesicles and viruses: are they close relatives? Proc. Natl Acad. Sci. USA 113, 9155\u20139161 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1689_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","volume":"21","author":"M Mathieu","year":"2019","unstructured":"Mathieu, M., Martin-Jaular, L., Lavieu, G. & Th\u00e9ry, C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9\u201317 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1689_CR42","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41551-022-00989-w","volume":"7","author":"Y You","year":"2023","unstructured":"You, Y. et al. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nat. Biomed. Eng. 7, 887\u2013900 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"1689_CR43","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar, M. et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell 184, 4919\u20134938.e22 (2021).","journal-title":"Cell"},{"key":"1689_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41551-019-0485-1","volume":"4","author":"Z Yang","year":"2020","unstructured":"Yang, Z. et al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat. Biomed. Eng. 4, 69\u201383 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1689_CR45","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"1689_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","volume":"12","author":"E Ruoslahti","year":"1996","unstructured":"Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697\u2013715 (1996).","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"1689_CR47","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1126\/science.2821619","volume":"238","author":"E Ruoslahti","year":"1987","unstructured":"Ruoslahti, E. & Pierschbacher, M. D. New perspectives in cell adhesion: RGD and integrins. Science 238, 491\u2013497 (1987).","journal-title":"Science"},{"key":"1689_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52002-4","volume":"15","author":"A Vu Hong","year":"2024","unstructured":"Vu Hong, A. et al. An engineered AAV targeting integrin alpha V beta 6 presents improved myotropism across species. Nat. Commun. 15, 7965 (2024).","journal-title":"Nat. Commun."},{"key":"1689_CR49","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/mus.880171210","volume":"17","author":"I Kinoshita","year":"1994","unstructured":"Kinoshita, I. et al. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17, 1407\u20131415 (1994).","journal-title":"Muscle Nerve"},{"key":"1689_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini, L. Gene therapy returns to centre stage. Nature 526, 351\u2013360 (2015).","journal-title":"Nature"},{"key":"1689_CR51","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","volume":"359","author":"CE Dunbar","year":"2018","unstructured":"Dunbar, C. E. et al. Gene therapy comes of age. Science 359, eaan4672 (2018).","journal-title":"Science"},{"key":"1689_CR52","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","volume":"9","author":"R Goswami","year":"2019","unstructured":"Goswami, R. et al. Gene therapy leaves a vicious cycle. Front. Oncol. 9, 297 (2019).","journal-title":"Front. Oncol."},{"key":"1689_CR53","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","volume":"40","author":"E Rohner","year":"2022","unstructured":"Rohner, E., Yang, R., Foo, K. S., Goedel, A. & Chien, K. R. Unlocking the promise of mRNA therapeutics. Nat. Biotechnol. 40, 1586\u20131600 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1689_CR54","first-page":"617","volume":"65","author":"S Horn","year":"2024","unstructured":"Horn, S. & Fehse, B. How safe is gene therapy?: second death after Duchenne therapy. Inn. Med. (Heidelb.) 65, 617\u2013623 (2024).","journal-title":"Inn. Med. (Heidelb.)"},{"key":"1689_CR55","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","volume":"22","author":"PB Shieh","year":"2023","unstructured":"Shieh, P. B. et al. Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial. Lancet Neurol. 22, 1125\u20131139 (2023).","journal-title":"Lancet Neurol."},{"key":"1689_CR56","unstructured":"Twenter, P. After patient\u2019s death, study cites potential barrier to Elevidys. Becker\u2019s Hospital Review https:\/\/www.beckershospitalreview.com\/pharmacy\/after-patients-death-study-cites-potential-barrier-to-elevidys\/ (2025)."},{"key":"1689_CR57","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1212\/WNL.0000000000203455","volume":"100","author":"F Muntoni","year":"2023","unstructured":"Muntoni, F. et al. EMBARK, a Phase 3 trial evaluating safety and efficacy of delandistrogene moxeparvovec (SRP- 9001) in Duchenne muscular dystrophy (DMD): study design and baseline characteristics (P5-8.012). Neurology 100, 3691 (2023).","journal-title":"Neurology"},{"key":"1689_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41434-024-00494-6","volume":"31","author":"G Baranello","year":"2024","unstructured":"Baranello, G. & Muntoni, F. AAV gene therapy for Duchenne muscular dystrophy: lessons learned from a phase 3 trial. Gene Ther. 31, 541\u2013543 (2024).","journal-title":"Gene Ther."},{"key":"1689_CR59","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG B\u00f6nnemann","year":"2023","unstructured":"B\u00f6nnemann, C. G. et al. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 388, 2294\u20132296 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1689_CR60","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/eurheartj\/ehae883","volume":"46","author":"Y You","year":"2025","unstructured":"You, Y. et al. Extracellular vesicle-mediated VEGF-A mRNA delivery rescues ischaemic injury with low immunogenicity. Eur. Heart J. 46, 1662\u20131676 (2025).","journal-title":"Eur. Heart J."},{"key":"1689_CR61","doi-asserted-by":"publisher","first-page":"30476","DOI":"10.1073\/pnas.2007443117","volume":"117","author":"RS Gormal","year":"2020","unstructured":"Gormal, R. S. et al. Modular transient nanoclustering of activated \u03b22-adrenergic receptors revealed by single-molecule tracking of conformation-specific nanobodies. Proc. Natl Acad. Sci. USA 117, 30476\u201330487 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01689-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01689-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:03:48Z","timestamp":1781168628000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01689-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":61,"alternative-id":["1689"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01689-5","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.J.L. and A.S.L. are shareholders of Spot Biosystems.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}